![Benzo[c][1,8]naphthyridin-6(5H)-one](https://file.medchemexpress.com/product_pic/hy-115862.gif "Click to View Benzo[c][1,8]naphthyridin-6(5H)-one Product Detail")
Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
14 Results for "
human Aurora A kinases
" in MedChemExpress (MCE) Product Catalog:
Products (14)
14 Results for "human Aurora A kinases" in MCE Product Catalog:
2
2 Cited Publications
Cat. No.: HY-18955
CAS No.: 1207293-36-4
Target:
Research Areas:
BI-847325 is an ATP competitive dual inhibitor of MEK and aurora kinases (AK) with IC50 values of 4 and 15 nM for human MEK2 and AK-C, respectively. BI-847325 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
Cat. No.: HY-137344A
Purity: 99.44%
Target:
Research Areas:
dAURK-4 hydrochloride is a selective AURKA PROTAC degrader. dAURK-4 hydrochloride promotes ubiquitination and degradation of AURKA . dAURK-4 hydrochloride can be used in the research of glioblastoma and multiple myeloma .
Target:
Research Areas:
Phthalazinone pyrazole is a potent, selective, and orally active inhibitor of Aurora-A kinase with an IC50 of 0.031 μM. Phthalazinone pyrazole can arrests mitosis and subsequently inhibit tumor growth via apoptosis of proliferating cells. Phthalazinone pyrazole suppresses the epithelial-mesenchymal transition (EMT) during the differentiation of hepatocyte-like cells (HLCs) from human embryonic stem cells .
Cat. No.: HY-137344
CAS No.: 2705844-81-9
Target:
Research Areas:
dAURK-4 is a selective AURKA PROTAC degrader. dAURK-4 promotes ubiquitination and degradation of AURKA . dAURK-4 can be used in the research of glioblastoma and multiple myeloma .
Cat. No.: HY-121998
CAS No.: 220088-42-6
Target:
Research Areas:
Binucleine 2 is an isoform-specific and ATP-competitive inhibitor of Drosophila Aurora B kinase (Ki=0.36 μM), a kinase involved in cell division. It is specific for Drosophila Aurora B kinase, inhibiting it in a dose-dependent manner, with minimal inhibition of human or X. laevis Aurora B kinases at concentrations up to 100 μM. Binucleine 2 induces mitotic and cytokinesis defects in Drosophila Kc167 cells. It prevents Drosophila S2 cells from assembling a contractile ring during cell division when used at a concentration of 40 μM but does not affect ring ingression, suggesting that Aurora B kinase activity is not required for that step.
Cat. No.: HY-W395613
CAS No.: 1389439-77-3
Target:
Research Areas:
TY-011 is an Aurora A/B kinase inhibitor. TY-011 induces abnormal microtubule-kinetochore attachment, leading to DNA damage and apoptosis (Apoptosis) in human gastric cancer cells, and ultimately inhibits cancer cell proliferation, with an IC50 value ranging from 0.11 to 4.49 μM in human gastric cancer cell lines. TY-011 has potential applications in gastric cancer research .
Cat. No.: HY-115862
CAS No.: 53439-81-9
Target:
Research Areas:
Benzo[c][1,8]naphthyridin-6(5H)-one exhibits low micromolar affinity to human adenosine receptor (AR) A1 and hA2A, with Ki of 4.6 and 4.8 μM. Benzo[c][1,8]naphthyridin-6(5H)-one is inhibitor for poly ADP-ribose polymerase-1 (PARP-1) and aurora kinase A, with IC50 of 0.311 and 5.5 μM .
Cat. No.: HY-114526
CAS No.: 1016971-82-6
Target:
Research Areas:
INH-13 is a Aurora inhibitor. INH-13 is applicable for cancer research .
Cat. No.: HY-187442
Target:
TDI6245 is a Aurora kinase A (AURKA) inhibitor with an IC50 value of 21.64 nM against AURKA. TDI6245 also inhibits the β5 subunit of the 20S proteasome from Plasmodium falciparum (Pf 20S), with IC50 values of 0.11 μM, 31.1 μM and 6.8 μM against Pf 20S β5, human constitutive proteasome β5c and human immunoproteasome β5i subunits, respectively. TDI6245 binds to the AURKA pocket and the substrate cleft of Pf 20S β5 via antiparallel β-sheets and hydrogen bonds. TDI6245 inhibits the growth of Plasmodium falciparum. TDI6245 can be used in research related to triple-negative breast cancer and malaria .
Cat. No.: HY-189295
Target:
Research Areas:
Aurora B/RET-IN-1 is a dual RET and Aurora B inhibitor with human IC50 values of 78 nM and 24 nM, respectively. Aurora B/RET-IN-1 binds the DFG-out conformation of RET as a type II inhibitor and extends into the allosteric pocket. Aurora B/RET-IN-1 inhibits Aurora B kinase activity. Aurora B/RET-IN-1 inhibits RET and Aurora B signaling pathways. Aurora B/RET-IN-1 can be used for research on non-small cell lung cancer .
Cat. No.: HY-183960
CAS No.: 890601-68-0
Target:
Research Areas:
BPyO-34 is a selective inhibitor of apoptosis signal-regulating kinase 1 (ASK1), with an IC50 of 0.52 μM against human targets. BPyO-34 inhibits the activity of ASK1 in in vitro kinase assays. BPyO-34 can be used in research related to various diseases such as diabetes and cancer .
Cat. No.: HY-181668
ULK1-IN-4 (compound 12i) is a ULK1 inhibitor with an IC50 of 4.7 μM against human ULK1, and it exhibits selectivity for Aurora A/Aurora B kinases. ULK1-IN-4 forms a covalent bond with the thiol group of the Cys182 residue of ULK1, thereby inhibiting the kinase activity of ULK1. ULK1-IN-4 inhibits the growth of colorectal cancer cells and exerts tumor-suppressive activity in a mouse model of colorectal cancer .
Cat. No.: HY-181311
Target:
Research Areas:
CCT400028 is a PROTACs-class degrader that targets the Aurora A (AURKA) kinase. CCT400028 induces ubiquitination and proteasomal degradation of target proteins by recruiting the cereblon (CRBN) E3 ubiquitin ligase. The KD values of CCT400028 against the three subtypes of human AURKA are 71 nM, 2100 nM and >10000 nM, respectively, and its IC50 against human CRBN is 6300 nM. CCT400028 is applicable to relevant research on leukemia, neuroblastoma and glioma .
Cat. No.: HY-119618
CAS No.: 303196-31-8
Target:
Research Areas:
R1498 is a multi-target kinase inhibitor with anti-angiogenic and anti-proliferative activities. R1498 mainly targets targets such as Aurora kinase and VEGFR2, which are associated with tumor development. R1498 showed moderate in vitro growth inhibition in a variety of tumor cells, with IC50 values in the micromolar range. R1498 showed anti-tumor efficacy superior to sorafenib in a variety of gastric cancer and hepatocellular carcinoma xenograft models, with tumor growth inhibition rates exceeding 80%, and tumor shrinkage was observed in some models. R1498 showed a 10-30% tumor shrinkage rate in three xenograft models derived from human primary gastric cancer tumors, further demonstrating its inhibitory potential. R1498 effectively inhibited Aurora A activity in vivo and reduced tumor vascularization .
- 1
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
